| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2026―Jun―02 |
2-Substituted oxazolyl and thiazolyl amino acids are suitable P1 surrogates for new SARS-CoV-2 main protease inhibitors |
Zijie Liu, Tayla J. Van Oers, Conrad Fischer, Anna Nguyen, Johnson Chew, John C. Vederas |
| 2 |
[GO] |
2026―Mrz―09 |
Ugi multicomponent reactions of optically active aldehydes and chiral aminoindanols: diastereoselective synthesis of bisamides relevant to SARS-CoV-2 Mpro inhibitors |
Arun K. Ghosh, Amlan Bhattacharjee, Uttara Jayashankar, Sydney N. Bogan, Andrew D. Mesecar |
| 3 |
[GO] |
2024―Aug―06 |
Dual SARS-CoV-2 and MERS-CoV Inhibitors from Artemisia monosperma: Isolation, Structure Elucidation, Molecular Modelling Studies, and In vitro Activities |
Ahmed M. Badawy, Marwa S. Donia, Nehal Gamal Qwaider, Mayada M. El-Ayouty, Osama G. Mohamed, Khaled Darwish, Ashootosh Tripathi, Safwat A Ahmed |
| 4 |
[GO] |
2024―Jul―01 |
Highly specific aptamer for SARS-CoV-2 Spike protein from the authentic strain |
Maria Khrenova, Lyudmila A. Nikiforova, Fedor Grabovenko, Nadezhda A. Orlova, Maria Sinegubova, Denis Kolesov, Elena Zavyalova, Maksim F. Subach, Igor Polyakov, Timofei S. Zatsepin, Maria Zvereva |
| 5 |
[GO] |
2024―Apr―24 |
Microwave-Assisted Synthesis of Highly Sulfated Mannuronate Glycans as Potential Inhibitors against SARS-CoV-2 |
Yirong Zhu, Xiaotong Wang, Siqian Lu, Jibin Zheng, Youling Liang, Liangliang Zhang, Pengfei Fang, Peng Xu, Biao Yu, You Yang |
| 6 |
[GO] |
2023―Dez―15 |
Two short approaches to the COVID-19 drug β-D-N4-hydroxycytidine and its prodrug molnupiravir |
Kevin E Persaud, Rajesh Sahu, Michelle C. Neary, Anant R. Kapdi, Mahesh K Lakshman |
| 7 |
[GO] |
2023―Aug―24 |
Hybrid molecules based on an emodin scaffold. Synthesis and activity against SARS-CoV-2 and Plasmodium |
Youzhi Li, Franck Touret, Xavier de Lamballerie, Michel Nguyen, Marion Laurent, Françoise Benoit-Vical, Anne Robert, Yan Liu, Bernard Meunier |
| 8 |
[GO] |
2023―Jun―09 |
Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19 |
Arun K. Ghosh, Monika Yadav |
| 9 |
[GO] |
2023―Apr―13 |
Synthesis of SARS-CoV-2 Mpro Inhibitors bearing a Cinnamic Ester Warhead with In Vitro Activity against Human Coronaviruses |
Andrea Citarella, Davide Moi, Martina Pedrini, Helena Pérez-Peña, Stefano Pieraccini, Alessandro Dimasi, Claudio Stagno, Nicola Micale, Tanja Schirmeister, Giulia Sibille, G Gribaudo, Alessandra Silvani, Clelia Giannini, Daniele Passarella |
| 10 |
[GO] |
2022―Sep―21 |
Facile access to 4’-(N-acylsulfonamide) modified nucleosides and evaluation of their inhibitory activity against SARS-CoV-2 RNA cap N7-guanine-methyltransferase nsp14 |
Romain Amador, Adrien Delpal, Bruno Canard, Jean-Jacques Vasseur, Etienne Decroly, Françoise Debart, Guillaume Clavé, Michael Smietana |
| 11 |
[GO] |
2022―Jan―26 |
Synthetic approaches to 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir ("Triazavirin®") active against SARS-CoV-2 (COVID-19) |
Grigory A. Аrtem'ev, Vladimir L. Rusinov, Dmitry S Kopchuk, Maria I. Savchuk, Sougata Santra, Evgeny Ulomsky, Grigory V Zyryanov, Adinath Majee, Weijie Du, Valery Charushin, Oleg N. Chupakhin |
|
